LEGISLATURE OF THE STATE OF IDAHO

Sixty-eighth Legislature First Regular Session - 2025

IN THE SENATE

SENATE BILL NO. 1036

BY HEALTH AND WELFARE COMMITTEE

AN ACT

RELATING TO HUMAN GENE THERAPY PRODUCTS; PROVIDING LEGISLATIVE INTENT; AMENDING CHAPTER 48, TITLE 39, IDAHO CODE, BY THE ADDITION OF A NEW SECTION 39-4810, IDAHO CODE, TO PROVIDE A SHORT TITLE, TO ESTABLISH A MORATORIUM ON CERTAIN USES OF HUMAN GENE THERAPY PRODUCTS, AND TO DEFINE A TERM; AND DECLARING AN EMERGENCY AND PROVIDING AN EFFECTIVE DATE.

Be It Enacted by the Legislature of the State of Idaho:

SECTION 1. LEGISLATIVE INTENT. It is the intent of the Legislature to protect Idaho adults and children from the adverse effects of experimental gene therapy and biologic products utilized as immunizations. By enacting this section, named in honor of Doug Cameron, the Legislature seeks to establish a moratorium on gene therapy immunizations to ensure the safety and well-being of all Idahoans. Doug Cameron, an Idaho rancher in excellent health, was severely injured immediately after receiving a genetic immunization encouraged by his employer. The injury left him disabled from the waist down, unable to walk, and confined to a wheelchair. His experience highlights the urgent need for caution, transparency, and rigorous oversight in the deployment of these treatments.

SECTION 2. That Chapter 48, Title 39, Idaho Code, be, and the same is hereby amended by the addition thereto of a NEW SECTION, to be known and designated as Section 39-4810, Idaho Code, and to read as follows:

39-4810. MORATORIUM ON CERTAIN USE OF HUMAN GENE THERAPY PRODUCTS. (1) This section shall be known and may be cited as the "Doug Cameron Act."

(2) The legislature finds that, in order to protect the health and safety of Idaho citizens, a moratorium on the administration of human gene therapy products in certain cases is necessary. No person in Idaho shall administer, by any route or modality, any human gene therapy product for any infectious disease indication, regardless of whether such administration is termed an immunization, vaccine, or any other term.

(3) For the purpose of this section, "human gene therapy product" means all products that mediate their effects by transcription or translation of transferred genetic material or by specifically altering human genetic sequences. Human gene therapy products include but are not limited to:

(a) Nucleic acids, such as plasmids and in vitro transcribed ribonucleic acid (RNA);

(b) Genetically modified microorganisms, such as viruses, bacteria, and fungi;

(c) Engineered site-specific nucleases used for human genome editing; and

(d) Ex vivo genetically modified human cells.

(4) The provisions of this section shall not apply to human gene therapy products utilized for treatment or therapy of cancer or genetic disorders.

(5) The moratorium described in this section shall remain in effect until July 1, 2035, subject to legislative review of available safety data.

SECTION 3. An emergency existing therefor, which emergency is hereby declared to exist, this act shall be in full force and effect on and after July 1, 2025.